APEX1 and neoplasm: APE/Ref-1 inhibitors have exhibited anti-proliferation and anti-angiogenesis activity against several human malignancies; therefore, we have chosen anti-tumor efficacy as an endpoint to rank the candidate compounds for bio-evaluation.